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ABSTRACT
Idiopathic portal hypertension (IPH) known as non-cirrhotic portal fibrosis (NCPF) is a constellation of liver 
disorders, in which liver cirrhosis is not present and the main clinical and pathological findings are encountered 
in the portal venous system. Patients usually come to hospital with esophageal varices and upper gastrointestinal 
bleeding; however, it is often misdiagnosed as liver cirrhosis. Its etiology is still unknown, but some evidences and 
epidemiological studies suggest that it is a multifactorial disease with genetic basis. The laboratory evaluation in 
IPH reveals only mild and subtle abnormalities predominantly related to hypersplenism. The major complications 
of IPH are esophageal varices and hypersplenism. Endoscopic sclerotherapy or band ligation, shunt surgery, 
and transjugular intrahepatic portosystemic shunt (TIPS) are modalities to treat the complications of IPH. The 
case report reported about diagnosis and treatment of a 20-year-old male with idiopathic portal hypertension. 
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ABSTRAK
Hipertensi portal idiopatik dikenal juga sebagai fibrosis portal non sirosis merupakan kumpulan kelainan 
hati tanpa adanya sirosis hati dan temuan klinis-patologi utamanya terletak pada sistem vena porta. Pasien 
biasanya datang ke rumah sakit dengan varises esofagus dan perdarahan saluran cerna atas, tetapi sering 
salah didiagnosis sebagai sirosis hati. Etiologi kelainan tersebut belum diketahui, tetapi dari beberapa bukti 
dan studi epidemiologi mengusulkan bahwa kelainan tersebut merupakan kelainan multifaktor dengan dasar 
genetik. Evaluasi laboratorium pada pasien hipertensi portal idiopatik hanya menunjukkan kelainan ringan, 
yang predominan berhubungan dengan hipersplenisme. Komplikasi utama hipertensi portal idiopatik adalah 
varises esofagus dan hipersplenisme. Endoskoskopi skleroterapi atau ligasi, bedah pembuatan pintas (shunt), 
dan transjugular intrahepatic portosystemic shunt (TIPS) merupakan modalitas untuk tata laksana komplikasi 
hipertensi portal idiopatik. Pada laporan kasus ini dilaporkan mengenai diagnosis dan tata laksana pasien 
laki-laki berusia 20 tahun, dengan hipertensi portal idiopatik.
Kata kunci: hipertensi portal idiopatik, fibrosis portal non sirosis, diagnosis, tatalaksana
INTRODUCTION
Idiopathic portal hypertension (IPH) known as non-
cirrhotic portal fibrosis (NCPF) is a constellation of 
liver disorders, in which liver cirrhosis is not present 
and the main clinical and pathological findings are 
encountered in the portal venous system.1 IPH is 
characterized by non-pathognomonic pathological 
changes (with the absence of cirrhosis) of the liver in 
addition to findings of portal hypertension. It is still 
one of the most important misdiagnoses of clinical 
practice. For many physicians, presenting esophageal 
varices and upper gastrointestinal bleeding usually 
prompt an unfortunate diagnosis of cirrhosis. 
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CASE ILLUSTRATION
A 20-year-old male came to emergency unit of 
Cipto Mangunkusumo Hospital with hematemesis 
melena since 12 hours before admission. The total 
volume of hematemesis melena was 400 mL. The 
patient did not complain any fever, nausea, abdominal 
pain, abdominal enlargement, dyspnea, edema, or 
scleral jaundice. The urine was clear yellow and no 
history of pale color of defecation. Since 1 year ago, 
the patient had been experiencing hematemesis melena 
for seven times and had undergone esophageal varices 
ligations for four times in other hospital. There was 
no history of chronic viral hepatitis as the risk factor.
On admission, the patient was in hypovolemic 
shock. The conjunctivas were pale with anicteric 
scleras. The heart and lung were normal. The abdomen 
was a little bit bloating, flexible, with non-palpable 
liver and there was splenomegaly (Schuffner V). 
Minimal shifting dullness was found. No abdominal 
pain was found as well as no stigmata of liver cirrhosis, 
edema of extremity, and flapping tremor. 
The laboratory results showed pancytopaenia with 
morphology of erythrocyte normocytic normochrome. 
The morphology of leukocyte and thrombocyte 
was normal with normal prothrombin time (PT), 
activated partial thromboplastin time (APTT), 
fibrinogen, and increased D-dimer. The level of alanine 
aminotransferase (ALT), aspartate transaminase 
(AST), bilirubin, alkaline phosphatase, albumin, and 
globulin were within normal limit. The renal function 
was normal. There was no evidence of hepatitis B, 
hepatitis C, or human immunodeficiency virus (HIV) 
infection. The level of cholinesterase and laboratory 
result of the autoimmune disease parameter were 
normal. The level of quantitative hepatitis B virus-
deoxyribonucleic acid (HBV-DNA) was examined, 
and the result revealed unidentified viral load.
A vascular Doppler ultrasound result indicated 
no thrombus, portal vein diameter 1.5 cm, splenic 
vein > 1.2 cm, and the umbilical vein was hardly 
evaluated (Figure 1). An abdominal ultrasound 
showed that the liver size was not attenuated, with 
inhomogen echostructure and irregular surface. The 
hepatic vein was unclear, portal vein and splenic 
vein were dilatated. A splenomegaly was found. The 
result of esophagogastroduodenoscopy (EGD) was 
esophageal varices grade III-IV with gastropathy portal 
hypertension (Figure 2).
An abdominal computed tomography scan (CT-
scan) showed liver enlargement, with firm surface, 
homogenous parenchyma, without dilatation of the 
intra-hepatic and extra-hepatic biliary tract, space 
occupying lesion (SOL), or nodule. The portal vein 
diameter was 1.6 cm without any thrombus. The spleen 
was large with size of 12.8 x 13.9 x 22.6 cm3. It pushed 
the intestinal gas into right lateral aspect and kidney 
to inferior. Splenic vein was large with diameter of 
1.7 cm. There was minimal ascites. 
Figure 1. Vascular doppler ultrasound showed dilatation of 
portal and hepatic vein
Figure 2. Esophagogastroduodenoscopy (EGD) showed 
gastropathy, esophageal varices grade III-IV with portal 
hypertension
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Analysis of ascites fluid revealed yellow color, 
clear fluid with negative Rivalta test, total cell count 
70/µL, polymorphonuclear (PMN) cells (segment) of 
67/µl, serum ascites albumin gradient  3.5. Cytology 
of the ascites fluid showed no malignancy. The first 
liver biopsy done prior the surgery showed an image 
of chronic hepatitis with histology activity index (HAI) 
grading of focal necrosis 0, piece-meal necrosis 1, HAI 
1 (mild), stage F3.
The final diagnosis were hematemesis melena 
caused by rupture of esophageal varices with a history 
of hypovolemic shock, idiopathic portal hypertension 
and, pancytopenia caused by hipersplenism. Fluid 
rescucitation and pack red cell transfusion were given 
until the patient had been recovered from hypovolemic 
shock. Hematemesis melena occurred only for one 
day and emergency endoscopy was performed. Other 
treatment included 2 x 40 mg intravenous omeprazole, 
4 x 15 ml oral sucralfate, oral hepatoprotector 3 x 1 
tablet, 3 x 10 mg intravenous vitamin K, 2 x 10 mg 
oral propranolol, 3 x 1 gram intravenous cefotaxime 
for 12 days, transfusion of platelets prior to ligation and 
surgery. There was no financial support for intravenous 
somatostatin therapy.  
A splenectomy and distal splenorenal shunt with 
end-to-side technique were performed with a prior 
vaccination of Meningococcus and Pneumococcus. 
Before and after the surgery, 3 x 1 gram ceftazidime 
was reintroduced. Intravenous ketorolac with 3 x 30 
mg of dose was given as an analgesic after the surgery. 
A second intraoperative liver biopsy was performed. 
It showed that the hepatocytes were in the lamellar 
arrangement, very mild lobular necrosis, dilatation of 
portal system, fibrosis with septa, and mild periportal 
necrosis. Portal vein and central vein were dilated and 
groups of hepatocytes containing blue granule in the 
cytoplasm were seen in VB stain. 
After the splenectomy and distal splenorenal shunt, 
the hemoglobin, leukocyte and platelet count increased. 
No complication was found in the surgery procedure. 
After surgery, the patient’s condition became better 
and the patient was discharged with a good condition.
DISCUSSION
Idiopathic portal hypertension (IPH) or non-
cirrhotic portal fibrosis (NCPF) is one of the important 
disease entities comprising non-cirrhotic portal 
hypertension, a group of diseases that are characterized 
by an increase in portal pressure, due to intrahepatic 
or prehepatic lesions, in the absence of cirrhosis of 
the liver.1,2 In the Indian subcontinent, it is known as 
non-cirrhotic portal fibrosis, while in Japan and other 
Asian countries, it is referred to as idiopathic portal 
hypertension.3,4
Although, the terms NCPF and IPH often have 
been used interchangeably, there are subtle differences 
between the two. NCPF is more common among male. 
The mean age of NCPF patients varies from 25 to 35 
years, which is much lower than patients who have 
IPH. Autoimmune features are common in IPH while 
rare in NCPF.5 Irregular parenchymal nodules and bile 
duct proliferations are more common in NCPF than 
IPH. Wedged hepatic venous pressure is almost normal 
in NCPF, while it is moderately raised in IPH. This 
case presents a male patient aged 20 years old, without 
any sign and result of an autoantibody disorder. These 
characteristics were suitable with a NCPF. However, 
in our institution, a term of IPH is more commonly 
used. In Japan, the yearly number of new cases ranged 
from 8 to 20, averaging 11 cases per year up to 1994.2
The pathogenesis of IPH is still not understood 
and there are some controversies about this subject. 
Although there are some theories on the pathogenesis 
of IPH, unfortunately none have been proven to be a 
single factor fully explaining the pathogenesis. These 
theories include the trace element-chemical theory, 
autoimmunity theory, infection theory, thrombosis 
theory, and genetic theory. IPH seems to be a multi-
factorial disease, in which two or more etiological 
factors may play a role.1
In this patient, the diagnosis of systemic lupus 
erythematosus has been ruled out. The ANA 
(anti-nuclear antibody) profile was negative and 
autoimmune hepatitis has been ruled out. The patient 
had never suffered from recurrent infection, especially 
gastrointestinal infection. But, because the patient 
lives in the tropical zone, such pathogenesis cannot 
be ruled out.2 The patient had undergone a Doppler 
ultrasound and abdominal multi-sliced computed 
tomography (MSCT) to rule out thrombosis cause and 
there was no thrombus found in the patient. Maruyama 
et al, showed that a contrast-enhanced ultrasound 
can differentiate IPH from liver cirrhosis. Delayed 
periportal enhancement on the sonograms based on 
perflubutane microbubble agent may be a characteristic 
of IPH.6 
A high degree of human leukocyte antigen DR3 
(HLA-DR3) aggregation was found in family members 
with IPH.1 There was a chance for this patient to 
have a high degree of HLA-DR3. But the laboratory 
examination was not done because it was not cost 
effective.1 
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The pathological findings in IPH are very 
heterogeneous.7 This heterogeneity is most probably 
due to changes occurring with the progression of the 
disease and changes in hepatic blood flow dynamics. 
Macroscopically, the liver may be atrophic and/
or nodular. Liver atrophy is a later finding in the 
course of the disease due to collapse of the peripheral 
liver architecture, along with ischemia related to 
hepatocyte drop-out via apoptosis. In this patient, a liver 
enlargement was found. In histological examination, the 
classical findings of IPH can be divided into two aspects. 
The primary finding directly related to IPH is intimal 
fibroelastic thickening of medium and small branches 
of the intrahepatic portal vein.8 The second aspect, 
resulting secondarily to obliterated portal branches, is 
aberrant neo-vascular formations, sinusoidal dilatation 
and hepatocellular nodular hyperplasia. These vessels 
play an important role in shunting blood flow from the 
obliterated portal segment towards unaffected sites. 
Biopsy material may show only mild and subtle changes 
from normal.2 
Nakanuma et al, proposed a staging of IPH with 
a combination of hepatic parenchymal atrophy and 
portal venous thrombosis. Stage I is non-atrophic liver 
without subcapsular parenchymal atrophy, stage II 
is non-atrophic liver with subcapsular parenchymal 
atrophy, stage III is atrophic liver with sub-capsular 
parenchymal atrophy, and stage IV is portal venous 
occlusive thrombosis. IPH livers can progress from stage 
I to stage III, while stage IV occurs relatively late.7 The 
patient in this case seemed to be on the stage I.
The patient has a relatively normal liver function, 
i.e. normal albumin level and prothrombin time, but 
he presents with variceal bleeding, which was detected 
in investigations of hypersplenism. Ascites is almost 
always a finding of advanced cases indicating the liver 
atrophies and residual capacity are limited.1 
Sarin et al, reported that 13.5% of patients 
had splenomegaly, 84.5% of patients had upper 
gastrointestinal bleeding, 92% of patients had 
esophageal varices, and 22.3% of patients had gastric 
varices.9 When they compared these patients with 
portal vein thrombosis patients, the IPH group was 
found to have larger spleens, but lower prevalence of 
ascites, gastric varices, history of upper gastrointestinal 
bleeding and almost no jaundice. Dhiman et al, 
reported that 96.7% of patients had splenomegaly and 
64.9% of patients had upper gastrointestinal bleeding.10 
Okuda et al, reported that the main presenting 
symptom of these patients were anemia related 
symptoms (26.2%),  hematemesis  (23.7%), 
splenomegaly (18.4%), and varices (84%) of all 
cases.11 The clear difference in presentation patterns 
suggests that there are two, non-homogenous IPH 
groups in those countries. This important clue has a 
very important and basic message, i.e. the Indian IPH 
population is formed of more chronic and advanced 
IPH cases than the Japanese and Western cases and it is 
one of the main causes of conflict in the IPH literature.1
The Asian Pacific Association of the Study of the 
Liver (APASL) divides the clinical manifestation 
into two groups, NCPF and IPH. In NCPF, the 
patient presents with well-tolerated episodes of 
gastrointestinal hemorrhage, splenomegaly, anemia, 
and consequences of hypersplenism. Development 
of ascites, jaundice, and hepatic encephalopathy is 
uncommon and may be seen only after an episode 
of gastrointestinal hemorrhage. Left upper quadrant 
pain due to perisplenitis and splenic infarction is not 
uncommon.2 The laboratory evaluation in IPH reveals 
only mild and subtle abnormalities predominantly 
related to hypersplenism.2 The parenchymal damage 
manifest by increased aminotransferase levels is very 
minimal in IPH. Results of conventional tests of liver 
function are normal or near normal.10
Pancytopenia caused by hypersplenism is found 
in the majority of patients with IPH. Whether the 
leucopenia in IPH increases susceptibility to infections, 
and whether splenectomy is required in such cases 
remain debatable. The bone marrow is hypercellular, 
which was shown in this patient by the increase of the 
reticulocyte count.2 
In this patient, the level of D-dimer increased, 
with normal PT, APTT, and fibrinogen. A state of 
mild, compensated, and disseminated intravascular 
coagulation secondary to endotoxemia or portosystemic 
collaterals has been reported in some cases of IPH, but 
it does not occur in this case report. A study by Bajaj et 
al, reported that 78% of IPH patients had a significantly 
increased international normalized ratio (INR) and a 
decrease in fibrinogen and platelet aggregation.12
The patients had a significant prolongation in partial 
thromboplastin time with increased levels of fibrinogen 
degradation products, which is usual in IPH. This 
suggests a mild-disseminated intravascular coagulation 
disorder in these diseases. However, previous study 
reported only low platelet aggregatability. Deficiency 
of proteins C and S has been proposed along with 
mutations in factor V Leiden; however, a cause-and-
effect hypothesis remains to be confirmed.2
The major complications of IPH can be summarized 
as esophageal varices and hypersplenism as shown in 
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this case report. The walls of these variceal veins are 
relatively thicker than the varices observed in cirrhosis. 
They rarely harbor “red-spots” that herald variceal 
bleeding. They are simply dilated veins that rarely 
complicate, and are relatively easy to treat compared to 
cirrhosis. Esophageal varices are reported to be found 
in 90% of the IPH patients. The principles and modes 
of management of esophageal varices remain the same 
as those for patients with cirrhosis. 
Bacterial infections are more common in patients 
with cirrhosis having variceal bleeding (35–66%) than 
in non-cirrhotic patients (5–7%).13 It has been shown 
that infected cirrhotic patients have a higher rate of 
variceal rebleeding (43%) than non-infected patients 
(10%).12 There is no study on the use of prophylactic 
antibiotics.9
Hirashita et al, conclude that 44% from 18 patients 
had portal vein thrombosis (PVT) after splenectomy. 
The mean interval until detection after splenectomy 
was 22 ± 41 months. But, there were no significant 
differences in the cumulative gastrointestinal bleeding 
and survival rates between patients with and those 
without PVT.14 
Vasoactive drugs, such as somatostatin, octreotide, 
or terlipressin, have been used in the treatment of acute 
variceal bleeding while endoscopic therapy is being 
arranged. However, there is no data on the efficacy 
of vasoactive drugs in IPH patient with acute variceal 
bleeding.
Endoscopic sclerotherapy and band ligation are 
effective in 80–90% of patients in controlling acute 
bleeding from esophageal varices and preventing 
rebleeding. Combination treatment with drugs plus 
endoscopic therapy is more effective than endoscopic 
therapy or drug therapy alone in controlling acute 
bleeding (88% vs. 76%) and preventing rebleeding 
for 5 days (77% vs. 58%), while there is no difference 
in mortality.15 
Failure of endoscopic therapy is defined, as further 
variceal bleeding after two endoscopic treatments 
during a single hospital admission for acute bleeding. 
The current therapies fail to control bleeding or 
prevent early rebleeding in 8–12% of patients, who 
should be treated by alternative modes of treatment 
like surgery or transjugular intrahepatic portosystemic 
shunt (TIPS).15
Endoscopic ligation can be performed as a primary 
prophylaxis for variceal bleeding. A decrease in the size 
of esophageal varices, as seen in patients with cirrhosis 
with an improvement in liver functions is unlikely in 
IPH, unless interventions like endoscopic sclerotherapy 
are applied, which after variceal obliteration results in 
the development of spontaneous splenorenal shunts.2
Shunt surgery for primary prophylaxis is likely to 
be indicated if the patient of IPH has large esophageal 
varices with a symptomatic large splenomegaly, a very 
low platelet count (< 20,000), stays far away from a 
good medical center where an upper GI bleeding can 
be tackled, or has a rare blood group.2  
Patients with gastric varices of more than 2 cm 
could be taken up for surgical shunt or balloon-
occluded retrograde transvenous obliteration if a 
splenorenal shunt is present, although studies are 
lacking.2 The selective distal spleno-renal shunt 
(DSRS) proposed has been considered to be the best 
procedure available for surgical decompression of 
patients with portal hypertension.16 Meta-analysis of 
the studies compared DSRS and sclerotherapy showed 
that DSRS significantly reduces the incidence of 
rebleeding and only slightly increases the occurrence 
of chronic encephalopathy, but does not improve 
survival.17
TIPS is an interventional radiology technique 
that has shown a 90% success rate to decompress 
the portal circulation. As a non-surgical intervention, 
without requirement for anesthesia and very low 
procedure-related mortality, TIPS is applicable to 
patients, who are otherwise untreatable, for example, 
nonsurgical candidates. Regarding esophago-gastric 
variceal bleeding, TIPS has excellent hemostatic 
effect (95%) with low rebleeding rate (< 20%). TIPS 
is an accepted rescue therapy for first line treatment 
failures in 2 settings (1) acute variceal bleeding and (2) 
secondary prophylaxis. In addition, TIPS offers 70 to 
90% hemostasis to patients presenting with recurrent 
active variceal bleeding.18 
Transjugular intrahepatic portosystemic shunt 
is more effective than standard therapy for patients 
with hepatic venous pressure gradient > 20 mmHg. 
Transjugular intrahepatic portosystemic shunt is 
particularly useful to treat bleeding from varices 
inaccessible to endoscopy. But, this procedure should 
not be applied for primary prophylaxis of variceal 
bleeding. Portosystemic encephalopathy and stent 
dysfunction are TIPS major drawbacks. 
If the patient were not treated well, the liver 
would have become atrophy, but it is not necessarily 
progressive, and the liver functional reserve is well 
maintained. Although mortality from variceal rupture 
is generally lower in IPH, because of better liver 
functions compared with cirrhosis, the major cause of 
death is variceal bleeding.1 Good prognostic features 
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in patients with IPH, a 2- and 5-year survival of nearly 
100% after successful eradication of esophagogastric 
varices, have been described.10 The incidence of portal 
vein thrombosis is higher in patients with IPH than in 
those with cirrhosis, but has a poor prognosis.1,2
From this case, we conclude that the patient has an 
idiopathic portal hypertension, with varying clinical 
pictures, including splenomegaly and recurrent variceal 
bleeding. Early diagnosis is needed to avoid delayed 
treatment. Although the prognosis is excellent, careful 
follow up and management of patients, with extra 
attention to treatment esophageal varices, is required. 
Further studies are essential in order to clarify the 
etiology and possible genetic background.
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